A phase II interventional clinical study (ClinicalTrials.gov Identifier: NCT01556191) involving Ful, an antiestrogen, has been completed, which aimed to study the effects of administration of Ful with EGFR-TKI on 379 female participants with advanced-stage NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.